Who
Peter B. Cancelmo
VP, General Counsel
Company insider
Files Form 4 as: VP, General Counsel, Omeros.
In numbers
- Trades disclosed
- 22
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $1.9M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 10 Jun 2019
- Last trade
- 31 Aug 2026
- Last filed
- 1 Sep 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Aug 2026filed 1 Sep 2026 | OMER OmerosBiotechnology | SEC FORM 4 Code M | $74K25,000 at $2.94 | filing |
| 31 Aug 2026filed 1 Sep 2026 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 31 Aug 2026filed 1 Sep 2026 | OMER OmerosBiotechnology | SEC FORM 4 Sold | $464K25,000 at $18.54 | filing |
| 31 Aug 2026filed 1 Sep 2026 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 31 Aug 2026filed 1 Sep 2026 | OMER OmerosBiotechnology | SEC FORM 4 Code M | $74K25,000 at $2.94 | filing |
| 31 Aug 2026filed 1 Sep 2026 | OMER OmerosBiotechnology | SEC FORM 4 Sold | $464K25,000 at $18.54 | filing |
| 28 Aug 2026filed 1 Sep 2026 | OMER OmerosBiotechnology | SEC FORM 4 Code M | $74K25,000 at $2.94 | filing |
| 28 Aug 2026filed 1 Sep 2026 | OMER OmerosBiotechnology | SEC FORM 4 Sold | $466K25,000 at $18.65 | filing |
| 28 Aug 2026filed 1 Sep 2026 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 28 Aug 2026filed 1 Sep 2026 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code M | —25,000 at $0.00 | filing |
| 28 Aug 2026filed 1 Sep 2026 | OMER OmerosBiotechnology | SEC FORM 4 Code M | $74K25,000 at $2.94 | filing |
| 28 Aug 2026filed 1 Sep 2026 | OMER OmerosBiotechnology | SEC FORM 4 Sold | $466K25,000 at $18.65 | filing |
| 22 Jul 2026filed 24 Jul 2026 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code A | —105,000 at $0.00 | filing |
| 22 Jul 2026filed 24 Jul 2026 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code A | —105,000 at $0.00 | filing |
| 30 Jun 2025filed 1 Jul 2025 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 25 Apr 2024filed 29 Apr 2024 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 22 Sep 2023filed 27 Sep 2023 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 21 Sep 2022filed 23 Sep 2022 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 2 Jul 2021filed 6 Jul 2021 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 26 Oct 2020filed 28 Oct 2020 | OMER Omerosoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
News
Omeros Stock Falls 12% After EMA Committee Reaffirms Negative Narsoplimab OpinionOMER · rttnews.com · 16 Oct 2026Omeros Receives Second CHMP Rejection For Narsoplimab In Europe; Stock DownOMER · rttnews.com · 16 Oct 2026Omeros Corporation Receives CHMP Negative Opinion Following Re-Examination of European Marketing Authorization Application for Narsoplimab in TA-TMAOMER · finanznachrichten.de · 16 Oct 2026
0 headlines in the last 90 days name Peter B. Cancelmo; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.